Gene Editing and Rett Syndrome: Does It Make the Cut?

Area of Science:

• Neurogenetics
• Molecular Biology
• Gene Therapy

Background:

• Rett syndrome (RTT) is a rare neurogenetic disorder caused by mutations in the Methyl CpG binding protein 2 (MECP2) gene.
• RTT presents with normal early development followed by regression in motor and communication skills, alongside comorbidities like epilepsy and cognitive impairment.
• Current treatments for RTT are symptomatic, with no cure available despite numerous clinical trials.

Purpose of the Study:

• To review current gene editing technologies for their potential application in treating Rett syndrome.
• To discuss the limitations and applicability of gene editing strategies for MECP2-related disorders.
• To highlight the need for therapies that achieve regulated MECP2 expression matching endogenous patterns.

Main Methods:

• Literature review of existing gene editing technologies.
• Analysis of the applicability of these technologies to the MECP2 gene locus.
• Discussion of the challenges in achieving spatiotemporal control of gene expression.

Main Results:

• Gene editing offers a novel therapeutic avenue for RTT by targeting the native MECP2 locus.
• Different gene editing technologies possess unique advantages and limitations for RTT treatment.
• Achieving precise, regulated MECP2 expression is crucial for therapeutic success.

Conclusions:

• Gene editing represents a promising strategy for developing curative therapies for Rett syndrome.
• Further research is needed to refine gene editing techniques for safe and effective MECP2 restoration.
• Understanding MECP2 expression dynamics is key to designing successful RTT gene therapies.